Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

2025-521143-20-00 · tracked via the Priya Life Science EU tracker

Sponsor

Amsterdam UMC Stichting

Sponsor type

Patient organisation/association

Therapeutic area

Diagnosis

Decision date

10/09/2026

Enrollment target

Sites

Netherlands

Condition studied

Bone Morphogenic Protein Receptor type 2 mutation carriers Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Metabolic dysfunction-associated Steatotic Liver Disease Pulmonary Arterial Hypertension Primary Sclerosing Cholangitis

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521143-20-00 on CTIS ↗ ← All trials in the EU